PE20011316A1 - Uso del acido [s-(r*,r*)]-hexahidro-6-[(2-mercapto-1-oxo-3-fenilpropil)amino-2,2-dimetil-7-oxo-1h-azepin-1-acetico como inhibidor de la vasopeptidasa para tratar hipertension sistolica aislada - Google Patents
Uso del acido [s-(r*,r*)]-hexahidro-6-[(2-mercapto-1-oxo-3-fenilpropil)amino-2,2-dimetil-7-oxo-1h-azepin-1-acetico como inhibidor de la vasopeptidasa para tratar hipertension sistolica aisladaInfo
- Publication number
- PE20011316A1 PE20011316A1 PE2001000306A PE2001000306A PE20011316A1 PE 20011316 A1 PE20011316 A1 PE 20011316A1 PE 2001000306 A PE2001000306 A PE 2001000306A PE 2001000306 A PE2001000306 A PE 2001000306A PE 20011316 A1 PE20011316 A1 PE 20011316A1
- Authority
- PE
- Peru
- Prior art keywords
- oxo
- phenylpropyl
- mercapto
- amino
- acid
- Prior art date
Links
- -1 2-MERCAPTO-1-OXO-3-PHENYLPROPYL Chemical class 0.000 title abstract 3
- 239000002253 acid Substances 0.000 title abstract 3
- 206010042957 Systolic hypertension Diseases 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 abstract 2
- 239000000460 chlorine Substances 0.000 abstract 2
- 229910052801 chlorine Inorganic materials 0.000 abstract 2
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 abstract 1
- WLRMANUAADYWEA-NWASOUNVSA-N (S)-timolol maleate Chemical compound OC(=O)\C=C/C(O)=O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 WLRMANUAADYWEA-NWASOUNVSA-N 0.000 abstract 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 abstract 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 abstract 1
- 239000002083 C09CA01 - Losartan Substances 0.000 abstract 1
- 239000002080 C09CA02 - Eprosartan Substances 0.000 abstract 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 abstract 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 abstract 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 abstract 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 abstract 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 abstract 1
- 239000000464 adrenergic agent Substances 0.000 abstract 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 abstract 1
- 229960002274 atenolol Drugs 0.000 abstract 1
- 229960005370 atorvastatin Drugs 0.000 abstract 1
- 230000003185 calcium uptake Effects 0.000 abstract 1
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 abstract 1
- 229960004195 carvedilol Drugs 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 208000029078 coronary artery disease Diseases 0.000 abstract 1
- 239000002934 diuretic Substances 0.000 abstract 1
- 229940030606 diuretics Drugs 0.000 abstract 1
- 229960004563 eprosartan Drugs 0.000 abstract 1
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 abstract 1
- YRSVDSQRGBYVIY-GJZGRUSLSA-N gemopatrilat Chemical compound O=C1N(CC(O)=O)C(C)(C)CCC[C@@H]1NC(=O)[C@@H](S)CC1=CC=CC=C1 YRSVDSQRGBYVIY-GJZGRUSLSA-N 0.000 abstract 1
- 229950006480 gemopatrilat Drugs 0.000 abstract 1
- 229960002003 hydrochlorothiazide Drugs 0.000 abstract 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 abstract 1
- 229960002198 irbesartan Drugs 0.000 abstract 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 abstract 1
- 229960004773 losartan Drugs 0.000 abstract 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 abstract 1
- 229960004844 lovastatin Drugs 0.000 abstract 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 abstract 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- LVRLSYPNFFBYCZ-VGWMRTNUSA-N omapatrilat Chemical compound C([C@H](S)C(=O)N[C@H]1CCS[C@H]2CCC[C@H](N2C1=O)C(=O)O)C1=CC=CC=C1 LVRLSYPNFFBYCZ-VGWMRTNUSA-N 0.000 abstract 1
- 229950000973 omapatrilat Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 abstract 1
- 229960002855 simvastatin Drugs 0.000 abstract 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 abstract 1
- 229960002961 ticlopidine hydrochloride Drugs 0.000 abstract 1
- MTKNGOHFNXIVOS-UHFFFAOYSA-N ticlopidine hydrochloride Chemical compound [H+].[Cl-].ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 MTKNGOHFNXIVOS-UHFFFAOYSA-N 0.000 abstract 1
- 229960005221 timolol maleate Drugs 0.000 abstract 1
- 229960004699 valsartan Drugs 0.000 abstract 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: a) UN INHIBIDOR DE LA VASOPEPTIDASA TAL COMO ACIDO [4S-[4O(R*),7O,10aß]]-OCTAHIDRO-4-[(2-MERCAPTO-1-OXO-3-FENILPROPIL)AMINO]-5-OXO-7H-PIRIDO[2,1-b][1,3]TIAZEPIN-7-CARBOXILICO DE FORMULA I (OMAPATRILAT) , EL ACIDO [S-(R*,R*)]-HEXAHIDRO-6-[(2-MERCAPTO-1-OXO-3-FENILPROPIL)AMINO-2,2-DIMETIL-7-OXO-1H-AZEPIN-1-ACETICO DE FORMULA II (GEMOPATRILAT) Y b) UN AGENTE HIPERTENSOR ENTRE ELLOS i) DIURETICOS COMO HIDROCLOROTIAZIDA, ii) AGENTES O-BLOQUEADORES Y/O ß-ADRENERGICOS COMO PROPANOLOL, MALEATO DE TIMOLOL, CARVEDILOL, ATENOLOL, iii) BLOQUEADORES DE LA ENTRADA DE CALCIO COMO AMLODIPINA, CLORHIDRATO DE DIALTIAZEM, CLORHIDRATO DE VERAPAMIL, iv) ANTAGONISTAS DEL RECEPTOR DE LA ANGIOTENSINA II COMO LOSARTAN, IRBESARTAN, VALSARTAN, EPROSARTAN, v) INHIBIDOR DE LA HMG-CoA-REDUCTASA COMO SIMVASTATINA, LOVASTATINA, ATORVASTATINA, ENTRE OTROS, vi) INHIBIDOR DE LA AGREGACION PLAQUETARIA COMO BISULFATO DE CLOPIDOGREL, CLORHIDRATO DE TICLOPIDINA, ASPIRINA. LA COMPOSICION ES UTIL PARA REDUCIR LA FRECUENCIA DE LA ENFERMEDAD CORONARIA Y EL TRATAMIENTO DE LA HIPERTENSION SISTOLICA AISLADA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19449900P | 2000-04-03 | 2000-04-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20011316A1 true PE20011316A1 (es) | 2002-01-13 |
Family
ID=22717832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2001000306A PE20011316A1 (es) | 2000-04-03 | 2001-04-03 | Uso del acido [s-(r*,r*)]-hexahidro-6-[(2-mercapto-1-oxo-3-fenilpropil)amino-2,2-dimetil-7-oxo-1h-azepin-1-acetico como inhibidor de la vasopeptidasa para tratar hipertension sistolica aislada |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20020004500A1 (es) |
| EP (1) | EP1267855A2 (es) |
| JP (1) | JP2003533440A (es) |
| AU (1) | AU2001287289A1 (es) |
| CA (1) | CA2405496A1 (es) |
| PE (1) | PE20011316A1 (es) |
| UY (1) | UY26648A1 (es) |
| WO (1) | WO2001074348A2 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU8054601A (en) * | 2000-07-13 | 2002-02-05 | Alteon Inc | Cyanomethyl substituted thiazoliums and imidazoliums and treatments of disordersassociated with protein aging |
| US6777443B2 (en) * | 2001-05-15 | 2004-08-17 | Novartis Ag | Dipeptide derivatives |
| WO2003053353A2 (en) * | 2001-12-20 | 2003-07-03 | Bristol-Myers Squibb Company | Administration of vasopeptidase inhibitors to reduce pulse pressure |
| US7468390B2 (en) | 2002-01-17 | 2008-12-23 | Novartis Ag | Methods of treatment and pharmaceutical composition |
| SI1467728T1 (sl) * | 2002-01-17 | 2008-02-29 | Novartis Ag | Farmacevtski sestavki vkljucujoci valsartan in NEP inhibitorje |
| EP1750862B1 (en) * | 2004-06-04 | 2011-01-05 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical composition containing irbesartan |
| WO2007045663A2 (en) * | 2005-10-19 | 2007-04-26 | Novartis Ag | Combination of an ati receptor antagonist and a np inhibitor fro treating ia hypertension and heartfailure |
| AR057882A1 (es) * | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
| US11622955B2 (en) * | 2017-11-28 | 2023-04-11 | Anavex Life Sciences Corp. | Sigma-1 receptor agonist systolic blood pressure therapy |
-
2001
- 2001-03-15 AU AU2001287289A patent/AU2001287289A1/en not_active Abandoned
- 2001-03-15 WO PCT/US2001/008240 patent/WO2001074348A2/en not_active Ceased
- 2001-03-15 JP JP2001572093A patent/JP2003533440A/ja active Pending
- 2001-03-15 EP EP01964664A patent/EP1267855A2/en not_active Withdrawn
- 2001-03-15 CA CA002405496A patent/CA2405496A1/en not_active Abandoned
- 2001-03-28 US US09/819,549 patent/US20020004500A1/en not_active Abandoned
- 2001-04-02 UY UY26648A patent/UY26648A1/es not_active Application Discontinuation
- 2001-04-03 PE PE2001000306A patent/PE20011316A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2405496A1 (en) | 2001-10-11 |
| JP2003533440A (ja) | 2003-11-11 |
| US20020004500A1 (en) | 2002-01-10 |
| AU2001287289A1 (en) | 2001-10-15 |
| UY26648A1 (es) | 2001-11-30 |
| WO2001074348A2 (en) | 2001-10-11 |
| WO2001074348A8 (en) | 2002-05-23 |
| EP1267855A2 (en) | 2003-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20060999A1 (es) | Composiciones farmaceuticas que contienen un diuretico y un bloqueador del receptor de angiotensina ii | |
| PE20011316A1 (es) | Uso del acido [s-(r*,r*)]-hexahidro-6-[(2-mercapto-1-oxo-3-fenilpropil)amino-2,2-dimetil-7-oxo-1h-azepin-1-acetico como inhibidor de la vasopeptidasa para tratar hipertension sistolica aislada | |
| ATE407679T1 (de) | Pyrimidin-2,4-dion-derivate als gonadotropin freisetzende hormon-rezeptor-antagonisten | |
| BRPI0412327A (pt) | derivados de pirimidina-2,4-diona como antagonistas de receptor de hormÈnio liberador de gonadotropina | |
| PE20040439A1 (es) | Combinacion de compuestos organicos | |
| PE20070803A1 (es) | Combinacion farmaceutica de un antagonista del receptor de angiotensina y un inhibidor de endopeptidasa neutra | |
| PE20121050A1 (es) | Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog | |
| PE20020802A1 (es) | COMPUESTO DE LACTAMA COMO INHIBIDOR DE LA LIBERACION DEL PEPTIDO ß-AMILOIDE | |
| UA84318C2 (ru) | Гетерополициклические соединения и их применение как метаботропических антагонистов рецепторов глутамата, фармацевтическая композиция на их основе | |
| PE107099A1 (es) | Composicion de atorvastatina y un antihipertensor | |
| AR045161A1 (es) | Derivados de quinazolina | |
| WO2005000807A3 (en) | Benzodiazepine cgrp receptor antagonists | |
| EP1074549A3 (en) | Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors | |
| PE20071164A1 (es) | Compuestos heterociclico fusionado como antagonista del receptor mineralocorticoide | |
| PE20011258A1 (es) | Derivados de benzocicloalquilenilamina como antagonistas de receptores muscarinicos | |
| PE20011114A1 (es) | Decahidro-isoquinolinas | |
| PL1620425T3 (pl) | Podstawione 3-cyjanotiofenoacetamidy jako antagoniści receptora glukagonu | |
| ECSP088967A (es) | Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia | |
| WO2007016087A3 (en) | Heterocyclic benzodiazepine cgrp receptor antagonists | |
| ATE324890T1 (de) | Zusammensetzung enthaltend einen angiotensin-ii- rezeptor-antagonist und einen diuretikum und deren verwendung zur behandlung von bluthochdruck | |
| WO2003031407A3 (en) | β-LACTAMYL VASOPRESSIN VlaANTAGONISTS | |
| BRPI0414663A (pt) | derivados triazol substituìdos como antagonistas de oxitocina | |
| WO2007061694A3 (en) | Spirohydantoin tricyclic cgrp receptor antagonists | |
| PE20060477A1 (es) | Compuestos piperazinodionas como antagonistas del receptor de oxitocina | |
| RU2006117790A (ru) | Применение производного пиразола для получения лекарственного средства, пригодного для профилактики и лечения дислипидемий и заболеваний, связанных с дислипидемиями и/или с ожирением |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |